✨
AI Summary
- Eisai discusses broadening Leqembi's use with subcutaneous version.
- Ongoing Phase III trials for pre-symptomatic Alzheimer's treatment.
- News from a Phase II study of a tau-targeting asset.
Guests on This Episode
MI
Michael Irizarry
1 podcast appearance